Spontaneous anti-PRAME antibodies were reported in a small proportion of patients with NSCLC expressing PRAME, as was also the case for NSCLC and melanoma expressing MAGE-A3.15, 16 In contrast, baseline antibodies to other tumour antigens such as NY-ESO-1 are detected more frequently (eg, 16% for NY-ESO-1 in patients with melanoma17). Here, PRAME is linked to melanoma.